Antiretroviral therapy coverage for PMTCT in Nepal
Nepal: Antiretroviral therapy coverage for PMTCT was 65.0% in 2024. ◆ Volatile
Antiretroviral therapy coverage for PMTCT in Nepal, 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.
Analysis
Nepal recorded 65.0% for antiretroviral therapy coverage for pmtct in 2024.
That represents a change of down 3.0% on the previous year and up 140.7% over ten years.
Over the whole period, antiretroviral therapy coverage for pmtct in Nepal peaked at 69.0% in 2022 and was at its lowest, 0.0%, in 2000.
Nepal ranks 58th of 84 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage for PMTCT in Nepal, year by year
| Year | % of pregnant women living with HIV | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 0.0% | — |
| 2004 | 0.0% | — |
| 2005 | 0.0% | — |
| 2006 | 6.0% | — |
| 2007 | 5.0% | -16.7% |
| 2008 | 8.0% | +60.0% |
| 2009 | 13.0% | +62.5% |
| 2010 | 9.0% | -30.8% |
| 2011 | 14.0% | +55.6% |
| 2012 | 18.0% | +28.6% |
| 2013 | 22.0% | +22.2% |
| 2014 | 27.0% | +22.7% |
| 2015 | 26.0% | -3.7% |
| 2016 | 43.0% | +65.4% |
| 2017 | 49.0% | +14.0% |
| 2018 | 40.0% | -18.4% |
| 2019 | 37.0% | -7.5% |
| 2020 | 40.0% | +8.1% |
| 2021 | 62.0% | +55.0% |
| 2022 | 69.0% | +11.3% |
| 2023 | 67.0% | -2.9% |
| 2024 | 65.0% | -3.0% |
Nepal compared with similar countries
- Nepal's 65.0% is below the median for lower middle income countries, which is 83.5%, 78% of the median. (32 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 3.2% | 0.0% | 13.0% | 10 |
| 2010s | 28.5% | 9.0% | 49.0% | 10 |
| 2020s | 60.6% | 40.0% | 69.0% | 5 |
Countries ranked near Nepal
More health data for Nepal
- Un projection of annual infant deaths, annual growth rate -1.95 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.8518 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,326 deaths per 1,000 people (2090)
- Number of infants who die before age 1 955 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 3 (2025)
- Population ages 00-04, female, annual growth rate -1.17 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0451 units per person (2025)
- Population ages 00-04, male, annual growth rate -2.11 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is antiretroviral therapy coverage for pmtct in Nepal?
- Antiretroviral therapy coverage for pmtct in Nepal was 65.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage for pmtct recorded in Nepal?
- The highest recorded value was 69.0% in 2022.
- What is the lowest antiretroviral therapy coverage for pmtct recorded in Nepal?
- The lowest recorded value was 0.0% in 2000.
- How does Nepal rank for antiretroviral therapy coverage for pmtct?
- Nepal ranks 58th out of 84 countries with data for 2024.
- Is antiretroviral therapy coverage for pmtct rising or falling in Nepal?
- Over the last ten years it is up 140.7%. The long-run trend across the full record is volatile.
- Where does this Nepal data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).